Aimmune Therapeutics, Inc. 3 SEC Filings

Filed On	Filing
24 Apr 2020	Form 3: Nestle Health Science Us Holdings, Inc., 10% owner and 4 others Holds 11,727,113 shares of Common Stock
24 Jan 2019	Form 3: Oxtoby Andrew, Chief Commercial Officer No securities owned
07 Nov 2018	Form 3: Haumann Brett K, Director No securities owned
19 Jun 2018	Form 3: Dallas Jayson Donald Alexander, Director No securities owned
01 May 2017	Form 3: Bjerkholt Eric, Chief Financial Officer No securities owned
23 Nov 2016	Form 3: Behar Gregory, Director No securities owned
23 Nov 2016	Form 3: Nestle Health Science Us Holdings, Inc., 10% owner and 2 others Holds 7,552,084 shares of Common Stock
19 Aug 2016	Form 3: Foresite Capital Management II, Llc, 10% owner and 4 others Holds 3,967,900 shares of Common Stock, $0.0001 par value
24 Jun 2016	Form 3: Adelman Daniel C Md, Chief Medical Officer No securities owned
06 Apr 2016	Form 3: Sheehy Douglas T., See Remarks No securities owned
04 Feb 2016	Form 3: Knapp Jeffrey H, Chief Operating Officer No securities owned
22 Jan 2016	Form 3: Barrowcliffe Susan E., General Manager, Europe
05 Aug 2015	Form 3: Raff Howard V., Chief Operating Officer Holds 428,575 shares of Common Stock, $0.0001 par value
05 Aug 2015	Form 3: Rozenman Mary M., See Remarks
05 Aug 2015	Form 3: Iwicki Mark T, Director
05 Aug 2015	Form 3: Dilly Stephen George, Director Holds 765,308 shares of Common Stock, $0.0001 par value
05 Aug 2015	Form 3: Elfont Robert Myles, Chief Medical Officer Holds 299,002 shares of Common Stock, $0.0001 par value
05 Aug 2015	Form 3: Enright Patrick G, Director
05 Aug 2015	Form 3: Falberg Kathryn E, Director Holds 69,894 shares of Common Stock, $0.0001 par value
05 Aug 2015	Form 3: Mcdade Mark, Director

Comments